Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Status:
RECRUITING
Trial end date:
2032-08-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
Phase:
NA
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University